ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Milei Threatens Falkland Oil Firms With Sanctions 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Add as a preferred source on Google
WALTHAM, Mass., Feb. 20, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming healthcare investor conferences.
- Canaccord Genuity 2018 Musculoskeletal Conference – New Orleans (March 6, 2018)
Adam Gridley, Histogenics’ CEO, will present a corporate overview on Tuesday, March 6, 2018 at 8:00 a.m. CT / 9:00 a.m. ET. The conference immediately precedes the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting and explores the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies.
- Cowen and Company 38th Annual Health Care Conference – Boston, MA (March 12-14, 2018)
Mr. Gridley will present a corporate overview on Wednesday, March 14, 2018 at 8:40 a.m. ET.
To access a live audio webcast of the presentations on the “Investor Relations” page of the Histogenics website, please click here. The webcasts will be available for approximately 45 days following the respective conferences.
About Histogenics Corporation
Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart®, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
